Skip to main content
SpringerLink
Log in

When to Start, What to Start and Other Treatment Controversies in Pediatric HIV Infection

  • Current Opinion
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Over the last decade there have been dramatic changes in the management of pediatric HIV infection. Whilst observational studies and several randomized control trials (RCTs) have addressed some questions about when to start antiretroviral therapy (ART) in children and what antiretrovirals to start, many others remain unanswered.

In infants, early initiation of ART greatly reduces mortality and disease progression. Treatment guidelines now recommend ART in all infants younger than 1 or 2 years of age depending on geographical setting.

In children >1 year of age, US, European (Paediatric European Network for Treatment of AIDS; PENTA) and WHO guidelines differ and debate is ongoing. Recent data from an RCT in Thailand in children with moderate immune suppression indicate that it is safe to monitor asymptomatic children closely without initiating ART, although earlier treatment was associated with improved growth.

Untreated HIV progression in children aged over 5 years is similar to that in adults, and traditionally adult treatment thresholds are applied. Recent adult observational and modeling studies showed a survival advantage and reduction of age-associated complications with early treatment. The current US guidelines have lowered CD4+ cell count thresholds for ART initiation for children aged >5 years to 500 cells/mm3.

Co-infections influence the choice of drugs and the timing of starting ART. Drug interactions, overlapping toxicities and adherence problems secondary to increased pill burden are important issues. Rapid changes in the pharmacokinetics of antiretrovirals in the first years of life, limited pharmacokinetic data in children and genetic variation in metabolism of many antiretrovirals make correct dosing difficult. Adherence should always be addressed prior to starting ART or switching regimens.

The initial ART regimen depends on previous exposure, including perinatal administration for prevention of mother to child transmission (PMTCT), adherence, co-infections, drug availability and licensing. A European cohort study in infants indicated that treatment with four drugs produced superior virologic suppression and immune recovery. Protease inhibitor (PI)-based ART has the advantage of a high barrier to viral resistance. A recent RCT conducted in several African countries showed PI-based ART to be advantageous in children aged <3 years compared with nevirapine-based ART irrespective of previous nevirapine exposure. Another trial in older children from resource rich settings showed both regimens were equally effective.

Treatment interruption remains a controversial issue in children, but one study in Europe demonstrated no short-term detrimental effects.

ART in children is a rapidly evolving area with many new antiretrovirals being developed and undergoing trials. The aim of ART has shifted from avoiding mortality and morbidity to achieving a normal life expectancy and quality of life, minimizing toxicities and preventing early cancers and age-related illnesses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII
Table VIII

Similar content being viewed by others

References

  1. Gray L, Newell ML, Thorne C, et al. Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics 2001 Jul; 108 (1): 116–22

    Article  PubMed  CAS  Google Scholar 

  2. Newell M-L, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364 (9441): 1236–43

    Article  PubMed  Google Scholar 

  3. World Health Organisation. Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Recommendations for a public health approach: 2010 revision [online]. Available from URL: http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html [Accessed 2011 Oct 4]

  4. CDC. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43 (RR-12): 1–10

    Google Scholar 

  5. Gibb DM, Hughes M, Dunn D, et al. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362 (9396): 1605–11

    Article  Google Scholar 

  6. Dunn D, Woodburn P, Duong T, et al. Current CD4 cell count and the short-term risk of aids and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008 Feb 1; 197 (3): 398–404

    Article  PubMed  Google Scholar 

  7. HPPMCS. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 2006 Jun 12; 20 (9): 1289–94

    Article  Google Scholar 

  8. Dunn D. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003 Nov 15; 362 (9396): 1605–11

    Article  PubMed  CAS  Google Scholar 

  9. Faye A, Le Chenadec J, Dollfus C, et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis 2004 Dec 1; 39 (11): 1692–8

    Article  PubMed  Google Scholar 

  10. Cross Continents Collaboration for Kids A, Writing Committee. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS 2008; 22 (1): 97–105

    Article  Google Scholar 

  11. Panel on Antiretroviral Therapy and Medical Management of HIV-infected Children. Guidelines for the use of antiretroviral therapy in paediatric HIV infection. National Institutes of Health, 2011 [online]. Available from URL: http://aidsinfo.nih.gov/contentfiles/PediatricGuidelines.pdf [Accessed 2012 Aug 11]

  12. Welch S, Sharland M, Lyall EGH, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009; 10 (10): 591–613

    Article  PubMed  CAS  Google Scholar 

  13. Goetghebuer TA, Haelterman E, Le Chenadec Jb, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 2009; 23 (5): 597–604

    Article  PubMed  Google Scholar 

  14. Newell ML, Patel D, Goetghebuer T, et al. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation? J Infect Dis 2006 Apr 1; 193 (7): 954–62

    Article  PubMed  CAS  Google Scholar 

  15. Abrams E, Wiener J, Carter R, et al. Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. AIDS 2003; 17 (6): 867–77

    Article  PubMed  Google Scholar 

  16. Judd A, Doerholt K, Tookey PA, et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV Infection during 1996–2006: planning for teenage and adult care. Clin Infect Dis 2007; 45 (7): 918–24

    Article  PubMed  Google Scholar 

  17. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008 Nov 20; 359 (21): 2233–44

    Article  PubMed  CAS  Google Scholar 

  18. Gibb DM, Newberry A, Klein N, et al. Immune repopulation after HAART in previously untreated HIV-1-infected children. Lancet 2000; 355 (9212): 1331–2

    Article  PubMed  CAS  Google Scholar 

  19. De Rossi A, Walker AS, Klein N, et al. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 2002 Aug 1; 186 (3): 312–20

    Article  PubMed  Google Scholar 

  20. Lobato MN, Caldwell MB, Ng P, et al. Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. Pediatric Spectrum of Disease Clinical Consortium. J Pediatr 1995 May; 126 (5 Pt 1): 710–5

    CAS  Google Scholar 

  21. Cooper ER, Hanson C, Diaz C, et al. Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection. Women and Infants Transmission Study Group. J Pediatr 1998 May; 132 (5): 808–12

    Article  PubMed  CAS  Google Scholar 

  22. Welch SB, Gibb D. When should children with HIV infection be started on antiretroviral therapy? PLoS Med 2008 Mar 25; 5 (3): e73

    Article  PubMed  Google Scholar 

  23. Walker AS, Doerholt K, Sharland M, et al. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 2004 Sep 24; 18 (14): 1915–24

    Article  PubMed  Google Scholar 

  24. Patel K, Hernan MA, Williams PL, et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis 2008 Feb 15; 46 (4): 507–15

    Article  PubMed  Google Scholar 

  25. McGrath CJ, Chung MH, Richardson BA, et al. Younger age at HAART initiation is associated with more rapid growth reconstitution. AIDS 2011 Jan 28; 25 (3): 345–55

    Article  PubMed  Google Scholar 

  26. Puthanakit T, Vonthanak S, Ananworanich J, et al. Randomized clinical trial of immediate versus deferred antiretroviral therapy initiation in children older than one year with moderate immunodeficiency: the PREDICT study (NCT00234091) [abstract no. TULBPE023]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2011 Jul 17–20; Rome

  27. Chiappini E, Galli L, Tovo PA, et al. Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy. BMC Infect Dis 2009; 9: 140

    Article  PubMed  Google Scholar 

  28. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for hiv on survival. N Engl J Med 2009; 360 (18): 1815–26

    Article  PubMed  CAS  Google Scholar 

  29. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009 Apr 18; 373 (9672): 1352–63

    Article  PubMed  Google Scholar 

  30. Castro H, Judd A, Gibb D, et al., Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiologic Research Europe (COHERE). Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet 2011; 377 (9777): 1580–7

    Article  PubMed  Google Scholar 

  31. Picat M-Q, Lewis J, Walker A, et al. Long-term profiles of CD4+ reconstitution in HIV+ children initiating ART: Uganda and Zimbabwe [abstract no. 967]. 19th Conference on Retroviruses and Opportunistic Infections (CROI); 2012 Mar 5–8; Seattle (WA)

  32. Early antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in hiv-infected adults (ANRS 12136 TEMPRANO) [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Oct 5]

  33. Strategic Timing of Anti-Retroviral Treatment (START) [online]. Available from URL: http://www.niaid.nih.gov/Volunteer/HIVandInfectious/HIVstudies/pages/startstudy.aspx [Accessed 2011 Oct 5]

  34. Havlir D, Ive P, Kendall M, et al. International randomized trial of immediate vs early ART in HIV+ patients treated for TB: ACTG 5221 STRIDE study [abstract no. 38]. 18th Conference on Retroviruses and Opportunistic Infections (CROI); 2011 Feb 27–Mar 2; Boston (MA)

  35. Karim SA, Naidoo K, Padayatchi N, et al. Optimal timing of ART during TB therapy: findings of the SAPiT trial. 18th Conference on Retroviruses and Opportunistic Infections (CROI); 2011 Feb 27–Mar 2; Boston (MA)

  36. Blanc F. Significant enhancement in survival with early (2 weeks) versus late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis [abstract no. THLBB106]. 18th International AIDS Conference; 2010 Jul 18–23; Vienna

  37. Laureillard D, Marcy O, Madec Y, et al. Incidence and risk factors of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in HIV-infected adults enrolled in the CAMELIA clinical trial (ANRS 1295/12160-CIPRA KH001/10425). 6th International AIDS Society on HIV Pathogenesis, Treatment and Prevention; 2011 Jul 17–20; Rome

  38. Pozniak AL, Coyne KM, Miller RF, et al. British HIV Association guidelines for the treatment of TB/HIV coinfection. HIV Med 2011; 12 (9): 517–24

    Article  PubMed  CAS  Google Scholar 

  39. European AIDS Clinical Society. European guidelines for treatment of HIV infected adults in Europe [online]. Available from URL: http://www.europeanaidsclinicalsociety.org [Accessed 2011 Dec 12]

  40. Panel on Medical Management and Antiretroviral Therapy in Adults, National Institutes of Health. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2012 Mar 27 [online]. Available from URL: http://www.aidsinfo.nih.gov [Accessed 2012 Aug 20]

  41. Yotebieng M, Van Rie A, Moultrie H, et al. Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS 2010 Jun 1; 24 (9): 1341–9

    Article  PubMed  CAS  Google Scholar 

  42. Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009 Sep 4; 58 (RR-11): 1–166

    PubMed  Google Scholar 

  43. Claret-Teruel GMDP, Noguera-Julian AMDP, Esteva CB, et al. Impact of human immunodeficiency virus coinfection on the progression of mother-to-child transmitted hepatitis C virus infection. Pediatr Infect Dis J 2011; 30 (9): 801–4

    Article  PubMed  Google Scholar 

  44. Operskalski EA, Kovacs A, Operskalski EA, et al. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011 Mar; 8 (1): 12–22

    Article  PubMed  Google Scholar 

  45. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE 2009; 4 (5): e5575

    Article  PubMed  Google Scholar 

  46. Sungkanuparph S, Filler SG, Chetchotisakd P, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis 2009 Sep 15; 49 (6): 931–4

    Article  PubMed  Google Scholar 

  47. Jullien V, Urien Sk, Hirt Db, et al. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother 2006 Nov; 50 (11): 3548–55

    Article  PubMed  CAS  Google Scholar 

  48. Neely M, Rakhmanina N. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. Clin Pharmacokinet 2011; 50 (3): 143–89

    Article  PubMed  CAS  Google Scholar 

  49. Saitoh A, Sarles E, Capparelli E, et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007 Oct 18; 21 (16): 2191–9

    Article  PubMed  CAS  Google Scholar 

  50. Lockman S, Shapiro L, Smeaton M, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356 (2): 135–47

    Article  PubMed  CAS  Google Scholar 

  51. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010 Oct 14; 363 (16): 1510–20

    Article  PubMed  CAS  Google Scholar 

  52. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression. JAMA 2010 Sep 8; 304 (10): 1082–90

    Article  PubMed  CAS  Google Scholar 

  53. Kuhn L, Coovadia A, Strehlau R, et al. Long-term outcomes of switching children to NVP-based therapy after initial suppression with a PI-based regimen. 18th Conference on Retroviruses and Opportunistic Infections (CROI); 2011 Feb 27–Mar 2; Boston (MA)

  54. LaPorte C, VanHeeswijk R, Mitchell C, et al. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children. Antivir Ther 2009; 14 (4): 603–6

    CAS  Google Scholar 

  55. Wittkop L, Gunthard HF, de Wolf F, et al., Eurocord-CHAIN Study Group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11 (5): 363–71

    Article  PubMed  Google Scholar 

  56. VanderFlier M, Verweel G, VanderKnaap L, et al. Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily. Antivir Ther 2008; 13 (8): 1087–80

    CAS  Google Scholar 

  57. Foissac F, Urien Sk, Hirt Db, et al. Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children. Antimicrob Agents Chemother 2011 Sep 1; 55 (9): 4320–5

    Article  PubMed  CAS  Google Scholar 

  58. Paediatric European Network for Treatment of AIDS. PENTA trials [online]. Available from URL: http://www.pentatrials.org/trials.htm [Accessed 2012 Aug 20]

  59. Königs C, Feiterna-Sperling C, Esposito S, et al. Pharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years, inclusive [abstract no. 879]. Conference on Retroviruses and Opportunistic Infections (CROI); 2009 Feb 16–19; Montreal

  60. Tudor-Williams G, Cahn P, Chokephaibulkit K, et al. Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced children and adolescents (6–17 years): week 24 primary analysis of the phase II PIANO study [abstract no. TULBPE027]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2011 Jul 17–20; Rome

  61. Briz V, Palladino C, Navarro M, et al. Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients. HIV Med 2011 Aug; 12 (7): 442–6

    Article  PubMed  CAS  Google Scholar 

  62. Palumbo P, Violari A, Lindsay J, et al. NVP- vs LPV/r-based ART among HIV+ infants in resource-limited settings: the IMPAACT P1060 trial [abstract no. 129LB]. 18th Conference on Retroviruses and Opportunistic Infections (CROI); 2011 Feb 27–Mar 2; Boston (MA)

  63. Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996 Oct 1; 174 (4): 713–21

    Article  PubMed  CAS  Google Scholar 

  64. Baylor M, Ayime O, Truffa M, et al. Hepatotoxicity associated with nevirapine use in HIV-infected children. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22–25; Boston (MA)

  65. Mulenga V, Cook A, Walker AS, et al. Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination baby pills in Zambia: a randomized controlled trial. Clin Infect Dis 2010 Nov 1; 51 (9): 1081–9

    Article  PubMed  CAS  Google Scholar 

  66. Babiker A, Castro HG, Compagnucci A, et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 2011; 11 (4): 273–83

    Article  PubMed  CAS  Google Scholar 

  67. EPPICC. Early antiretroviral therapy in HIV-1 infected infants in Europe, 1996–2008: treatment response and duration of first line regimens. AIDS 2011 Oct 3; 25 (18): 2279–87

    Google Scholar 

  68. Green H, Gibb DM, Walker AS, et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS 2007; 21 (8): 947–55

    Article  PubMed  CAS  Google Scholar 

  69. Nahirya-Ntege PMD, Musiime VMD, Naidoo BD, et al. Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. Pediatr Infect Dis J 2011; 30 (6): 535–7

    PubMed  Google Scholar 

  70. Musiime V, Kendall L, Bakeera-Kitaka S, et al. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Antivir Ther 2010; 15 (8): 1115–24

    Article  PubMed  CAS  Google Scholar 

  71. Pediatric European Network for Treatment of AIDS (PENTA). Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. Antivir Ther 2010; 15 (3): 297–305

    Article  Google Scholar 

  72. Bergshoeff A, Burger D, Verweij C, et al. Plasma pharmacokinetics of once-versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther 2005; 10 (2): 239–46

    PubMed  CAS  Google Scholar 

  73. Munderi P, Walker AS, Kityo C, et al. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med 2010; 11 (5): 334–44

    Article  PubMed  CAS  Google Scholar 

  74. Kumar PN, Salvato P, Lamarca A, et al. A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). AIDS Res Ther 2009; 6: 3

    Article  PubMed  Google Scholar 

  75. Ribaudo HJ, Kuritzkes DR, Gulick RM. A comparison of three initial antiretroviral AIDS regimens. N Engl J Med 2007 Sep 6; 357 (10): 1056–7

    Article  PubMed  CAS  Google Scholar 

  76. Neely M, Rutstein R, Bianco GD, and the LEGACY Consortium, editors. Safety and efficacy of NRTI-only antiretroviral regimens in HIV-infected children. 17th Conference on Retroviruses and Opportunistic Infections; 2010 February 16–19; San Francisco (CA)

  77. Dart Virology Group, Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20 (10): 1391–9

    Article  Google Scholar 

  78. ARROW. Antiretroviral research for Watoto [online]. Available from: http://www.controlled-trials.com [Accessed 2011 Oct 10]

  79. Cohen K, Meintjes G. Management of individuals requiring ART and TB treatment. Current Opinion in HIV and AIDS 2010; 5 (1): 61–9

    Article  PubMed  Google Scholar 

  80. Oudijk JM, Mcilleron H, Mulenga V, et al., editors. Pharmacokinetics of nevirapine in young children during combined ART and rifampicin-containing antituberculosis treatment. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2009 Jul 19–22; Cape Town

  81. Kwara A, Ramachandran G, Swaminathan S. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert Opin Drug Metab Toxicol 2010 Jan; 6 (1): 55–68

    Article  PubMed  CAS  Google Scholar 

  82. Shah I, Swaminathan S, Ramachandran G, et al. Serum nevirapine and efavirenz concentrations and effect of concomitant use of rifampicin in HIV infected children on antiretroviral therapy. Indian Pediatr 2011; 48 (12): 943–7

    Article  PubMed  Google Scholar 

  83. Ren Y, Nuttall J, Egbers C, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2008; 47 (5): 566–9

    Article  PubMed  CAS  Google Scholar 

  84. Frohoff C, Moodley M, Fairlie L, et al. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS ONE 2011; 6 (2): e17273

    Article  PubMed  CAS  Google Scholar 

  85. McIlleron H, Ren Y, Nuttall J, et al. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther 2011; 16 (3): 417–21

    Article  PubMed  CAS  Google Scholar 

  86. Parienti J-J, Bangsberg DR, Verdon R, et al. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009 Feb 15; 48 (4): 484–8

    Article  PubMed  Google Scholar 

  87. Barro M, Some J, Foulongne V, et al. Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname. J Acquir Immune Def Syndr 2011 1; 57 Suppl. 1: S44–9

    CAS  Google Scholar 

  88. Cotton M, Violari A, Gibb D, et al. Early ART followed by interruption is safe and is associated with better outcomes than deferred ART in HIV+ infants: final results from the 6-year randomized CHER trial [abstract no. 28LB]. 19th Conference on Retroviruses and Opportunistic Infections (CROI); 2012 Mar 5–8; Seattle (WA)

  89. Wamalwa D, Benki-Nugent S, Langat A, et al. Treatment interruption in infants following 24 months of empiric ART: Kenya [abstract no. 27]. 19th Conference on Retroviruses and Opportunistic Infections (CROI); 2012 Mar 5–8; Seattle (WA)

  90. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006 Nov 30; 355 (22): 2283–96

    Article  PubMed  CAS  Google Scholar 

  91. Gibb D, on behalf of the PENTA Writing Committee. Response to planned treatment interruptions in HIV infection varies across childhood. AIDS 2010 Jan 16; 24 (2): 231–41

    Article  Google Scholar 

  92. Reynolds SJ, Kityo C, Hallahan CW, et al. A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS One 2010; 5 (4): e10307

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors have no conflicts of interest to declare and have received no financial assistance in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Paediatric Infectious Diseases Specialist & Chief of Service, Paediatrics, St Mary’s Hospital, Imperial College NHS Trust, South Wharf Rd, London, W2 1INY, UK

    Anna Turkova, Rachel H. Webb &  Hermione Lyall

Authors
  1. Anna Turkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel H. Webb
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hermione Lyall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hermione Lyall.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Turkova, A., Webb, R.H. & Lyall, H. When to Start, What to Start and Other Treatment Controversies in Pediatric HIV Infection. Pediatr Drugs 14, 361–376 (2012). https://doi.org/10.1007/BF03262417

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262417

Keywords

Search

Navigation